All rights to NMP 179 revert to Matritch immediately.
Matritech and Sysmex mutually agreed to terminate their agreement related to use of the former’s nuclear matrix protein (NMP) associated with cervical cancer and cervical precancerous conditions. All rights licensed in the agreement thus revert to Matritech.
The 2002 transaction granted Sysmex exclusive, worldwide rights to use NMP 179 technology for automated, nonslide-based laboratory instruments. Sysmex planned to combine the product with flow cytometry to develop an automated process to screen cervical cell specimens.
This discontinuation comes shortly after Inverness Medical Innovations reported intentions to purchase Matritech for $36 million in stock.
